Health Catalyst Inc (NASDAQ: HCAT)’s stock price has dropped by -9.09 in relation to previous closing price of 6.49. Nevertheless, the company has seen a loss of -20.27% in its stock price over the last five trading days. prnewswire.com reported 2025-01-13 that SALT LAKE CITY, Jan. 13, 2025 /PRNewswire/ — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced a multi-year partnership with OrthoNebraska, a leading provider of orthopedic care headquartered in Omaha, Nebraska. Through this partnership, OrthoNebraska will leverage Health Catalyst Ignite™, a data and analytics ecosystem supported by best-in-class cross-industry technologies, healthcare-specific data models, self-service tools, and industry expertise in one modern, scalable environment.
Is It Worth Investing in Health Catalyst Inc (NASDAQ: HCAT) Right Now?
Moreover, the 36-month beta value for HCAT is 1.37. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for HCAT is 58.53M and currently, short sellers hold a 4.52% of that float. On January 15, 2025, HCAT’s average trading volume was 546.42K shares.
HCAT’s Market Performance
HCAT stock saw a decrease of -20.27% in the past week, with a monthly decline of -29.43% and a quarterly a decrease of -27.52%. The volatility ratio for the week is 10.18%, and the volatility levels for the last 30 days are 6.55% for Health Catalyst Inc (HCAT). The simple moving average for the past 20 days is -17.30% for HCAT’s stock, with a -18.05% simple moving average for the past 200 days.
Analysts’ Opinion of HCAT
Many brokerage firms have already submitted their reports for HCAT stocks, with KeyBanc Capital Markets repeating the rating for HCAT by listing it as a “Overweight.” The predicted price for HCAT in the upcoming period, according to KeyBanc Capital Markets is $9 based on the research report published on January 08, 2025 of the current year 2025.
Evercore ISI gave a rating of “Outperform” to HCAT, setting the target price at $11 in the report published on January 03rd of the previous year.
HCAT Trading at -23.86% from the 50-Day Moving Average
After a stumble in the market that brought HCAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.63% of loss for the given period.
Volatility was left at 6.55%, however, over the last 30 days, the volatility rate increased by 10.18%, as shares sank -26.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.62% lower at present.
During the last 5 trading sessions, HCAT fell by -20.27%, which changed the moving average for the period of 200-days by -20.70% in comparison to the 20-day moving average, which settled at $7.13. In addition, Health Catalyst Inc saw -16.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HCAT starting from LeSueur Daniel, who sale 5,209 shares at the price of $7.51 back on Jan 06 ’25. After this action, LeSueur Daniel now owns 91,253 shares of Health Catalyst Inc, valued at $39,134 using the latest closing price.
Landry Benjamin, the General Counsel of Health Catalyst Inc, sale 2,500 shares at $7.52 during a trade that took place back on Jan 06 ’25, which means that Landry Benjamin is holding 72,250 shares at $18,796 based on the most recent closing price.
Stock Fundamentals for HCAT
Current profitability levels for the company are sitting at:
- -0.21 for the present operating margin
- 0.36 for the gross margin
The net margin for Health Catalyst Inc stands at -0.26. The total capital return value is set at -0.13. Equity return is now at value -21.46, with -10.37 for asset returns.
Based on Health Catalyst Inc (HCAT), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at 1.03. The interest coverage ratio of the stock is -5.56.
Currently, EBITDA for the company is -68.28 million with net debt to EBITDA at -1.11. When we switch over and look at the enterprise to sales, we see a ratio of 1.31. The receivables turnover for the company is 5.85for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
To wrap up, the performance of Health Catalyst Inc (HCAT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
